Seed rounds are on the rise, making up 42% of total deals, compared to 21% in 2019<\/span><\/strong><\/span><\/a>. <\/p>\n\n\n\n AI-focused startups alone raised $4.8 billion this year, signaling that the future of healthcare is being shaped by cutting-edge technology. <\/p>\n\n\n\n Here are the U.S.-based healthcare and healthtech startups that raised $100 million or more so far in 2024:<\/p>\n\n\n\n Maven Clinic, a women\u2019s healthcare startup, raised $125 million<\/span><\/strong><\/span><\/a> in its latest funding round, bringing its total funding to over $425 million. Founded in 2014, Maven offers clinical support for preconception, pregnancy, parenting, and menopause. With over 2,000 clients across 175 countries, Maven partners with employers and health plans to provide accessible healthcare for women.<\/p>\n\n\n\n Triveni Bio, a biotech company focused on antibody treatments for immunological and inflammatory (I&I) disorders, raised $115 million<\/span><\/strong><\/span><\/a> in Series B funding. The round was led by Goldman Sachs Alternatives, with participation from Fidelity Management & Research, Deep Track Capital, and existing investors. The funds will help expand Triveni’s therapeutic pipeline aimed at addressing significant healthcare needs in the I&I space.<\/p>\n\n\n\n Glooko, a digital platform for managing chronic conditions like diabetes, raised $100 million<\/span><\/strong><\/span><\/a> in Series F funding. The round was led by Georgian, with additional investments from Health Catalyst Capital and Canaan. This will help expand its product offerings, including data insights and device integrations. Glooko also appointed Mike Alvarez as CEO. Previously, the company raised $30 million in Series D funding in 2021.<\/p>\n\n\n\n Zing Health, a Medicare Advantage insurer focused on chronic special needs plans, raised $140 million<\/span><\/strong><\/span><\/a> in a recent funding round. The investment was led by Health 2047 Capital Partners, CRG, and First Trust Capital Partners, with support from existing investors like Newlight Partners and Town Hall Ventures. Founded in 2019, Zing Health serves nearly 13,000 members, with 62% enrolled in C-SNPs.<\/p>\n\n\n\n Aktis Oncology, a clinical-stage biotech firm specializing in targeted alpha radiopharmaceuticals for cancer treatment, secured $175 million<\/span><\/strong><\/span><\/a> in an oversubscribed Series B financing. The round was led by RA Capital Management, with co-leads RTW Investments and Janus Henderson Investors. Based in Boston, Aktis Oncology aims to advance its pipeline of innovative cancer therapies targeting solid tumors with this new funding. <\/p>\n\n\n\n Devoted Health, a tech-driven Medicare Advantage provider based in Waltham, MA, secured an additional $112 million<\/span><\/strong><\/span><\/a> in Series E funding. This round, backed by The Space Between, Cox Enterprises, and White Road Capital, will support the company’s expansion into seven new states. With a total post-money valuation of $12.87 billion, this round caps off a year of impressive funding for the company, which also raised a $1.15 billion Series D round in 2021. Devoted Health was founded in 2017 by brothers Todd and Ed Park.<\/p>\n\n\n\n Spring Health raised $100 million<\/span><\/strong><\/span><\/a> in Series E funding, boosting its valuation to $3.3 billion. Led by Generation Investment Management, this round will help expand global access to mental healthcare. The company\u2019s AI-powered platform now serves over 10 million lives across 400 employers and strategic payer partnerships, improving access to mental health services through 10,000+ providers.<\/p>\n\n\n\n Spring Health has secured $100 million<\/span><\/strong><\/span><\/a> in Series E funding, increasing its valuation to $3.3 billion. The round was led by Generation Investment Management, with participation from Kinnevik, William K. Warren Foundation, RRE, and Northzone. Since its founding eight years ago, Spring Health has expanded its employer benefit program to cover over 10 million lives across 400 employers. Using AI, the company enhances the speed and effectiveness of mental health care, connecting users to a network of over 10,000 providers for faster access to support.<\/p>\n\n\n\n AKASA, a provider of AI solutions for the healthcare revenue cycle, has raised $120 million<\/span><\/strong><\/span><\/a> in its Series C round, bringing its total funding to $205 million. Based in San Francisco, AKASA\u2019s platform focuses on automating revenue cycle management, addressing challenges like rising volumes and staffing shortages. Investors such as Andreessen Horowitz, Costanoa Ventures, and Bond supported the round. The funds will help AKASA enhance its AI-driven platform, which integrates cutting-edge technology with expert revenue cycle management to tackle pressing healthcare finance issues.<\/p>\n\n\n\n Formation Bio, an AI-native pharma company, has secured $372 million<\/span><\/strong><\/span><\/a> in Series D funding, led by a16z with support from Sanofi and other major investors like Sequoia and Thrive. This financing will fuel the expansion of its AI-driven drug development platform and the growth of its drug pipeline. Formation Bio is leveraging AI to automate workflows, such as generating patient recruitment content and adverse event reports in record time. These advancements reflect its commitment to innovation in both drug development and operational efficiency.<\/p>\n\n\n\n Karius, a leader in genomic diagnostics for infectious diseases, has raised $100 million<\/span><\/strong><\/span><\/a> in Series C funding. The round was co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from existing investors such as Softbank Vision Fund 2 and General Catalyst. This funding will help Karius expand its reach beyond the 400 U.S. hospitals currently using the Karius Test. The test leverages genomic analysis and AI to detect over 1,000 pathogens from a single blood sample, revolutionizing the approach to infectious disease diagnostics.<\/p>\n\n\n\n Transcarent secured $126 million<\/span><\/strong><\/span><\/a> in Series D funding, raising its valuation to $2.2 billion with $450 million in total funding. Led by General Catalyst and 7wireVentures, the round includes new investors like Geodesic Capital. The funds will enhance AI-driven features, support growth, and advance Transcarent\u2019s mission to simplify and lower healthcare costs.<\/p>\n\n\n\n Aetion, a real-world evidence platform analyzing data to evaluate medical products, secured $110 million<\/span><\/strong><\/span><\/a> in Series C funding led by Warburg Pincus. This round doubles its lifetime funding to $212 million. The funding will enhance Aetion\u2019s platform, grow its commercial team, and expand its presence in Europe and Asia-Pacific. Known for its partnership with the FDA during COVID-19, Aetion continues to drive innovation in healthcare analytics.<\/p>\n\n\n\n Xaira Therapeutics, headquartered in the San Francisco Bay Area, launched with a record-breaking $1 billion<\/span><\/strong><\/span><\/a> funding commitment, the largest initial investment ever by Arch Venture Partners. The biotech startup combines cutting-edge AI with insights from functional genomics and proteomics to pioneer transformative drug discovery.<\/p>\n\n\n\n NexHealth, a leading patient experience platform based in the San Francisco Bay Area, raised $125 million<\/span><\/strong><\/span><\/a> in a Series C funding round, valuing the company at $1 billion. The round was led by Buckley Ventures, with participation from notable investors such as Lachy Groom, Jack Altman, and Packy McCormick. The funding supports NexHealth\u2019s mission to enhance patient experiences, streamline administrative tasks for providers, and develop a universal API for healthcare developers to create innovative solutions.<\/p>\n\n\n\n Mirador Therapeutics raised over $400 million<\/span><\/strong><\/span><\/a>, led by ARCH Venture Partners with contributions from OrbiMed and Fairmount. The biotech company, founded by Mark McKenna (ex-CEO of Prometheus Biosciences), is focused on precision therapies for immune-mediated inflammatory and fibrotic diseases. Its proprietary Mirador360 platform enables precise diagnostics and patient stratification for efficient clinical development.<\/p>\n\n\n\n Zephyr AI has secured $111 million<\/span><\/strong><\/span><\/a> in Series A funding to further enhance its AI solutions for precision medicine. The round was led by Revolution Growth, with participation from Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group. The new capital will support Zephyr AI in accelerating its analytical capabilities and expanding its collection of training and validation data sets to better democratize precision medicine.<\/p>\n\n\n\n Abridge, a startup specializing in AI-powered clinical documentation tools, has raised $150 m<\/span><\/strong><\/span><\/a>i<\/span><\/strong><\/span><\/a>llion<\/span><\/strong><\/span><\/a> in a Series C funding round, bringing its valuation to $850 million. The round was led by Lightspeed Venture Partners and Redpoint Ventures, following a valuation jump from over $200 million in its last funding round just four months ago. Abridge automates clinical notes and medical conversations for doctors, streamlining the documentation process and improving efficiency in healthcare settings.<\/p>\n\n\n\n Freenome, a biotechnology company focused on blood tests for early cancer detection, has raised $254 million<\/span><\/strong><\/span><\/a> in new funding from both new and existing investors. The company is advancing its pipeline of early detection tests for colorectal and lung cancers, leveraging its multiomics platform. Freenome is currently conducting registration studies for these tests as it aims to improve early diagnosis through innovative, non-invasive technologies. The valuation at which the funds were raised has not been disclosed.<\/p>\n\n\n\n Cour Pharmaceuticals, a Chicago-based biotech company focused on developing treatments for autoimmune diseases, has closed a $105 million<\/span><\/strong><\/span><\/a> funding round. The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from prominent investors such as Roche Venture Fund, Pfizer’s Breakthrough Growth Initiative, Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund. <\/p>\n\n\n\n OnCusp Therapeutics has successfully raised $100 million<\/span><\/strong><\/span><\/a> in an oversubscribed Series A round, bringing its total funding since its establishment in 2021 to $139 million. The financing was led by Novo Holdings, OrbiMed, and F-Prime Capital, with additional participation from both new and existing investors. The funds will be used to advance OnCusp’s portfolio of assets aimed at improving cancer treatments for patients.<\/p>\n\n\n\n Lykos, a California-based company specializing in MDMA therapy for PTSD, has raised $100 million<\/span><\/strong><\/span><\/a> in Series A funding. This investment will help the company advance its efforts to gain FDA approval for its ecstasy-based therapy. The funding supports Lykos’ goal to contribute to the growing field of psychedelic-assisted therapy, including initiatives from MAPS (Multidisciplinary Association for Psychedelic Studies).<\/p>\n\n\n\n Healthcare startups are addressing some of the most pressing issues in the industry today. <\/p>\n\n\n\n A major challenge is improving patient care<\/strong>. Traditional healthcare systems often suffer from inefficiencies and delays, but startups are using technology to streamline processes. By offering personalized care, faster diagnoses, and more accessible treatment, they\u2019re making healthcare better for patients.<\/p>\n\n\n\n Another challenge is the rising cost of healthcare<\/strong>. As costs continue to climb, patients and providers alike feel the pressure. Many startups are focusing on reducing these costs by leveraging telemedicine, AI, and automation. These solutions make healthcare more affordable without compromising on quality.<\/p>\n\n\n\n Data privacy<\/strong> is also a big concern, especially with sensitive health information being shared and stored digitally. Startups are creating solutions to protect patient data and ensure it remains secure while still improving healthcare delivery.<\/p>\n\n\n\n By solving these challenges, these startups are paving the way for a more efficient, affordable, and secure healthcare system.<\/p>\n\n\n\n These healthcare startups are changing the game with innovative technology<\/strong>. From AI to genomics, they\u2019re revolutionizing how we diagnose, treat, and care for patients.<\/p>\n\n\n\n Take Maven Clinic<\/strong>, for example. It\u2019s not just about offering healthcare; it\u2019s about offering it when and where women need it most. By focusing on women\u2019s health\u2014from preconception to menopause\u2014Maven is redefining how care can be personalized and accessible. <\/p>\n\n\n\n More women are getting the support they need, without the traditional barriers of waiting times and limited access.<\/p>\n\n\n\n Then there\u2019s Spring Health<\/strong>. It\u2019s tackling mental health in a big way. Using AI, Spring Health is making mental health care faster and more effective. Their platform connects employees to mental health services, reducing wait times and improving the quality of care. <\/p>\n\n\n\n This is especially important as mental health continues to be a top concern across industries.<\/p>\n\n\n\n These startups aren\u2019t just innovating with technology. They’re transforming traditional healthcare delivery models. They’re not waiting for the system to catch up\u2014they’re leading the way. <\/p>\n\n\n\n In 2023, health tech startups secured $25 billion<\/span><\/strong><\/span><\/a> in VC funding, proving it\u2019s a top investment sector, despite a 35% drop from 2021.<\/p>\n\n\n\nOctober<\/h2>\n\n\n\n
September<\/h2>\n\n\n\n
August<\/h2>\n\n\n\n
July<\/h2>\n\n\n\n
June<\/h2>\n\n\n\n
May<\/h2>\n\n\n\n
April<\/h2>\n\n\n\n
March<\/h2>\n\n\n\n
February<\/h2>\n\n\n\n
January<\/h2>\n\n\n\n
Major Healthcare Challenges These Startups Are Tackling<\/h2>\n\n\n\n
![\"\"](\"https:\/\/www.syscreations.ca\/blog\/wp-content\/uploads\/2024\/11\/Case-Study-How-We-Developed-HIPAAPHIPAPIPEDA-Compliant-Telemedicine-App.jpg\")
<\/a><\/figure>\n\n\n\nHow These Startups Are Transforming the Industry: Impact on Healthcare Innovation<\/h2>\n\n\n\n
![\"\"](\"https:\/\/www.syscreations.ca\/blog\/wp-content\/uploads\/2024\/11\/Related-How-to-Build-a-Women-Health-App-5-App-Ideas-for-Women-Health-Startups.jpg\")
<\/a><\/figure>\n\n\n\n![\"\"](\"https:\/\/www.syscreations.ca\/blog\/wp-content\/uploads\/2024\/11\/Related-A-Detailed-Breakdown-of-How-to-Cost-to-Start-a-Mental-Health-Startup.jpg\")
<\/a><\/figure>\n\n\n\nWhat Are the Key Trends in Health Tech Investments?<\/h2>\n\n\n\n